The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Zhao Ch Guang, MD
- Phone Number: +86136673520046
- Email: 562122649@qq.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410000
- Recruiting
- Xiangya Hospital, Central South University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age >18 years old
- identify the patients infected with novel coronavirus pneumonia;
- the patient completed CT examination;
- sign the informed consent.
Exclusion Criteria:
- age < 18;
- those who cannot complete cardiopulmonary ultrasound according to the a-ccue process;
- the patient or his guardian requests to withdraw from the researcher;
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
characteristics of cardiopulmonary ultrasound
Time Frame: 30 mins
|
Complete the examination of cardio-pulmonary ultrasound in accordance with the a-ccue process of patients with novel coronavirus bedside.
To summarize and analyze the characteristics of cardiopulmonary ultrasound in patients with novel coronavirus pneumonia
|
30 mins
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
assess the relationship between pulmonary ultrasound imaging score and National Early Warning Score(NEWS) and prognosis.
Time Frame: 2-3weeks
|
assess the relationship between pulmonary ultrasound imaging score and National Early Warning Score(NEWS) and prognosis.
|
2-3weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
evaluate two kinds of evaluation methods for the evaluation of patients with lung condition effects are consistent or not, and verify consistency of ultrasonic evaluation method and the way of CT evaluation.
Time Frame: 3 hours
|
Auto line B is a method which is based on artificial intelligence is used to calculate the lungs ultrasonic B line numbers reviewing the status of patients with lung, and also evaluate patients' lungs using the traditional artificial semi-quantitative method, to evaluate those two kinds of evaluation methods for the evaluation of patients with lung condition effects are consistent or not
|
3 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Zhang Li Na, MD, Xiangya Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 202003028
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Novel Coronavirus Pneumonia
-
NCT04281693UnknownNovel Coronavirus Infection Pneumonia
-
NCT04285190WithdrawnCoronavirus Disease 2019 | Novel Coronavirus Pneumonia
-
NCT04275388Unknown2019 Novel Coronavirus Pneumonia
-
NCT05305456CompletedNovel Coronavirus Pneumonia
-
NCT04273763Unknown
-
NCT04365309UnknownAspirin | Treatment | Novel Coronavirus Pneumonia
-
NCT04282902UnknownPneumonia | Novel Coronavirus Pneumonia | Pirfenidone